Anavex Life Sciences delays filing quarterly report for June 30, 2026 quarter
AVXL•CEO change and prior delinquency
Christopher Missling was terminated as CEO on April 30, 2026; Terrie Kellmeyer was appointed interim CEO on May 4, 2026.
The company was also reported as delinquent on its Form 10-Q for the quarter ended March 31, 2026.
Anavex said no significant change in results of operations is anticipated versus the prior-year period.
Late Form 10-Q filing tied to board review
Anavex Life Sciences filed a late notice for its Form 10-Q for the quarter ended June 30, 2026, missing the Aug. 10, 2026 deadline.
The delay was tied to additional time needed to prepare and review the filing amid a board special committee review linked to the CEO termination.
